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Abstract
Background: Meteorin-like (Metrnl) is an adipokine with insulin sensitizing and anti-inflammatory properties that
has been discovered recently. The relation among Metrnl, Inflammatory Bowel Disease (IBD), and obesity has been
unexplored yet.
Methods: The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn’s
disease (CD) patients who were diagnosed by pathological examination. In all participants, serum levels of
adiponectin, Metrnl, interleukin (IL)-6, and Tumor necrosis factor (TNF-α) were measured using ELISA kits.
Results: Metrnl concentration was considerably lower in both UC (85.25 ± 36.55 pg/mL) and CD (76.93 ± 27.92 pg/
mL) patients in comparison to control (107.52 ± 35.33 pg/mL). In addition, it was seen that both patient groups
have a decreased level of adiponectin compared to the controls. Besides that, the level of IL-6 and TNF-α were
significantly greater in the patient groups. Moreover, the result showed that the level of Metrnl is inversely
correlated with body mass index (BMI) in the controls and the patients. Metrnl levels are also inversely associated
with IL-6, and TNF-α in both of the patient groups.
Conclusions: The current study is the first one reporting the decreased levels of Metrnl in serum among patients
with IBD, which is inversely related with BMI, TNF-α, and IL-6. These results suggested a possible relation of Metrnl
with the pathogenesis of IBD, particularly through inflammatory process, although further studies are warranted to
dissect the possible mechanism.
Keywords: Meteorin-like, Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Interleukin, Tumor necrosis
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Background
Inflammatory Bowel Disease (IBD) as one of the causes
of mortality in modern societies, characterized by gastro-
intestinal chronic inflammation [1, 2]. Two most com-
mon and pathologic types of IBD are Crohn’s disease
and ulcerative colitis (UC). The exact etiology of IBD is
not well-understood yet,, therefore no-definitive cure
has been identified [3]. In spite of previous research
which showed that a possible association of underweight
and malnutrition with the occurrence of IBD, recent
studies have revealed about 15–40% of patients with IBD
are obese and 20–40% are overweight which might con-
tribute to the development of IBD [4]. Recent epidemio-
logical studies have also shown that incidence of IBD is
rising in parallel with obesity prevalence [4, 5]. More-
over, the rate of hospitalization and surgery are more
frequent among IBD patients with obesity [6]. Scientific
studies have suggested that, genetics, gut microbiome,
and the immune system may play critical roles in IBD,
however, this has not completely understood yet [7].
IBD (UC and CD) also displays the characteristics of
chronic inflammation and metabolic syndrome, that in-
duces effective changes in metabolism [8, 9]. Adipocyto-
kines are secreted by white adipose tissue which have
effect on the gut microbiome, inflammation, and metab-
olism pathways [10, 11]. In a mutual way, IBD also can
be considered as a risk factor for obesity via changing in
the intestinal microbial metabolism [9, 12].
On the other hand, the impaired white adipose tissue
(WAT) function such as abnormal adipocytokine secre-
tion has a major and effective role on the inflammatory
condition in colon tissue [12]. In this way, it was observed
that, leptin concentration was decreased in the serum
sample obtained from the IBD patients (with or without
overweight). While the levels of resistin, adiponectin, and
active ghrelin were remarkably increased [13].
Meteorin-like (Metrnl, known as Subfatin) is a novel
adipo-myokine that is mainly expressed in WAT, how-
ever, it was reported that Metrnl is also expressed in
colon epithelium. The anti-inflammatory function of
Metrnl has been revealed recently and also has other
roles including enhancing lipid metabolism, decreasing
adipose inflammation, and ameliorating obesity-
mediated insulin resistance (IR) [14]. Notably, Metrnl
expression was higher in mesenteric WAT of the CD pa-
tients in comparison to the controls [15]. Metrnl is
highly expressed in intestinal cells, white adipose tissue,
and skin and also expressed in other tissues including
muscle, liver, heart, spleen, and central nervous system
(CNS). Moreover, the activated macrophages produced
Metrnl, which by this fact, it may be connected to the
inflammatory disorders such as IBD [16]. A few studies
have been conducted on tissue Metrnl levels in IBD dis-
ease. So far, no studies have been performed on
investigating the association between serum Metrnl and
IBD disease as well as the association among this pro-
tein, obesity, and the pro-inflammatory cytokines. Re-
garding to the fact that IBD is an inflammatory disease
and Metrnl anti-inflammatory activities, in this study,
the levels of Metrnl in serum were examined in the pa-
tients with inflammatory bowel disease and also its asso-
ciation was assessed with the hall-markers of




This case-control study was conducted on 54 control
subjects (42 male and 12 female) and 85 IBD patients in-
cluding 42 UC (31 male and 11 female) and 43 CD (28
male and 15 female) who were recruited from endoscopy
unit of Valiasr Hospital, Birjand, Iran. All the individuals
aged between 35 and 60 years old. The patient and con-
trol groups were selected by clinical examination, radio-
logic, endoscopic, and pathologic criteria. Normal people
without any inflammatory diseases was considered as
control group and based on age, gender and BMI were
matched with patient groups. The inclusion criteria for
patients were as following; were diagnosed by radiologic,
endoscopic examination according to clinical and patho-
logical guideline documents, and presence of other IBD’s
manifestations including diarrhea, abdominal pain, rectal
bleeding, and malnutrition. In addition, none of them
were received medication or anti-inflammatory drugs.
All of patients were diagnosed recently. Written consent
form was obtained from all participants. The diagnosis
of UC/CD were based on established clinical and histo-
pathological criteria. Moreover, the subjects were ex-
cluded with any history of cancer, diabetes, autoimmune
diseases or active infectious disease.
Anthropometric data and laboratory measurements
Demographic data and medical history were obtained by
a self-questionnaire from all participants. At the begin-
ning of examinations, weight and height were taken
from participants who were wearing light clothes, with-
out shoes. Body mass index (BMI) was also calculated by
body weight (kg) divided by height squared (m2), and
studied targets were categorized into normal weight
(BMI < 25) and overweight (BMI ≥ 25). Systolic and dia-
stolic blood pressures of all the participants were mea-
sured using a standard sphygmomanometer after 15 min
resting in a sitting posture. After 12-h of fast, 5 mL of
venous blood was obtained from all the participants and
the serum was separated by centrifugation. Subse-
quently, fasting blood sugar (FBS) and lipid profiles in-
cluding triglycerides (TG), total cholesterol (TC), High-
density lipoprotein-cholesterol (HDL-C), and Low-
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density lipoprotein-cholesterol (LDL-C) were measured
using auto-analyzer and the commercially available kits
(Pars Azmoon, Tehran, Iran).
Serum adipokine and cytokines
Circulating levels of Metrnl were evaluated using an im-
munoassay kit (R&D Systems, Minneapolis, USA,
Cat#DY7867). Moreover, the inter-assay and intra-assay
variations were calculated as 6 and 8%, respectively. Adi-
ponectin serum levels were measured using an ELISA
kit (Adipogen, Seoul, South Korea, Cat#AG-45A-
0001YEK-K101) with inter- and intra-assay variations of
4.4 and 4.6%, respectively. Afterward, the ultrasensitive
ELISA kits were used to measure the serum levels of
inteleukin-6 (IL-6) (R & D Systems, Minneapolis, USA,
Cat# HS600B) and TNF-α (R & D Systems, Minneapolis,
USA, Cat# DTA00C). Notably, the minimum detectable
ranges of IL-6 and TNF-α were obtained as 0.7 and 1.6
pg/mL. Inter and intra-assay variations of IL-6 were 9
and 7% and inter and also intra-assay variations of TNF-
α were 6 and 5%, respectively.
Statistical analysis
Statistical analysis was performed using SPSS version 18.
Categorical data was analyzed using chi-square test and
presented in frequency and percentage. Continuous vari-
ables were also examined by student t-test and one-way
ANOVA, and presented in mean and standard deviation
(SD). Pearson correlation test was applied to correlation
analysis. Furthermore, multinomial logistic regression
was conducted to estimate the risk of diseases status ac-
cording to serum levels of Metrnl.
Results
Anthropometric and biochemical measurement
The anthropometric and biochemical variables of the
studied population are presented in Table 1. There is no
significant difference in terms of age, sex, and BMI. In
addition, there were no significant difference in the fre-
quency of normal weight and overweight between the
groups. Although FBS illustrated no significant differ-
ence between the controls and patients with UC and
CD, insulin and homeostatic model assessment for insu-
lin resistance (HOMA-IR) were dramatically higher in
the CD patients compared to the controls. It should be
noted that, higher levels of insulin and HOMA-IR in the
UC patients compared to the controls did not reach to
the significant threshold. Furthermore, lipids profile in-
cluding TG, TC, HDL-C, and LDL-C and systolic blood
pressure (SBP) and diastolic blood pressure (DBP)
Table 1 Anthropometric and biochemical characteristic of studied population
Control (n = 54) UC (n = 42) CD (n = 43) P value
Sex (male/female) 42/12 31/11 28/15 0.373
BMI (kg/m2) 24.12 ± 3.56 23.45 ± 3.64 24.43 ± 4.61 0.502
Normal weight / over weight 29/25 26/16 21/22 0.473
Age (year) 39.02 ± 4.6 38.24 ± 5.32 38.74 ± 5.7 0.763
SBP (mmHg) 131.17 ± 20.79 133.40 ± 24.26 131.65 ± 23.97 0.887
DBP (mmHg) 81.63 ± 13.11 83.10 ± 14.48 83.16 ± 14.26 0.825
FBG (mg/dL) 90.26 ± 9.03 93.65 ± 13.27 94.28 ± 12.05 0.172
Insulin (μU/mL) 4.03 ± 0.31 5.66 ± 0.5 5.93 ± 0.64b* 0.014
HOMA-IR 0.89 ± 0.07 1.31 ± 0.14 1.43 ± 0.17b** 0.005
TG (mg/dL) 117.41 ± 44.83 128.76 ± 47.64 126.08 ± 38.15 0.409
TC (mg/dL) 157.22 ± 35.41 164.54 ± 47.49 162.25 ± 30.83 0.629
LDL-C (mg/dL) 94.70 ± 26.95 100.64 ± 35.84 104.93 ± 21.74 0.212
HDL-C (mg/dL) 43.53 ± 6.20 42.11 ± 9.07 41.46 ± 7.76 0.394
Adiponectin (μg/mL) 10.29 ± 3.35 7.88 ± 2.83a** 7.44 ± 2.44b** < 0.001
TNF-α (pg/mL) 16.08 ± 5.50 29.62 ± 7.40a** 30.43 ± 8.25b** < 0.001
IL-6 (pg/mL) 6.38 ± 3.51 8.28 ± 4.11 9.17 ± 4.18b** 0.002
Metrnl (pg/mL) 107.52 ± 35.33 76.93 ± 27.92a** 85.25 ± 36.55b** < 0.001
Data are presented as Mean ± SD
One way ANOVA and Tukey’s multiple comparisons test were used for comparison of quantitative variables
Abbreviations: UC ulcerative colitis, CD Crohn’s disease, SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, HOMA-IR homeostasis
model assessment of insulin resistance, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TC total cholesterol, TG triglyceride
a Comparison between control and UC
b Comparison between control and CD
*P < 0.05
**P < 0.01
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demonstrated no considerable variation between the pa-
tients and controls.
Serum levels of adipokines and cytokines
The ELISA results (Fig. 1) showed that, adiponectin con-
centration was considerably lower in the patients with
UC and CD compared to the controls. Furthermore, an
elevated level of TNF-α in the patients in comparison to
the controls was observed. Moreover, patients with CD
showed higher IL-6 levels compared to the controls,
while this figure for the serum levels of IL-6 did not
reach to the significant threshold in the patients with
UC. Furthermore, a decreased concentration of Metrnl
serum was observed in the patients with UC and CD
compared to the controls.
Regarding the crucial role of adipose tissue on Metrnl
levels, analysis was performed according to the BMI cut-
off (Overweight, BMI ≥ 25 and normal weight, BMI <
25). In this regard, Metrnl serum levels were found to be
lower in all the overweight subgroups (Table 2).
Association of serum Metrnl with the risk of diseases
status
Multinomial logistic regression was performed to assess
the risk of diseases status according to serum levels of
Metrnl. The results demonstrated a significant associ-
ation between the decreased levels of Metrnl with the
risk of UC and CD diseases. Furthermore, these associa-
tions have been adjusted for confounding factors includ-
ing age, sex and BMI and the relationships remained as
significant for both UC and CD diseases (Table 3).
Fig. 1 Serum levels of adipokines and cytokines. a Serum levels of adiponectin decreased significantly in both UC and CD patients compared to
controls. b Serum levels of TNF-alpha were found to be lower in both patient groups compared to controls. c IL-6 serum concentration indicated
a considerable increase in CD group compared to controls. d Metrnl serum levels demonstrated a significant decline in UC and CD patients
compared to controls. CD, Crohn’s disease; IL-6, Interleukin 6; TNF-α, Tumor Necrosis Factor Alpha; UC, ulcerative colitis
Table 2 Serum levels of Metrnl according to BMI cutoff
Group Normal weight Overweight P
All participants 102.27 ± 36.23 78.13 ± 31.04 < 0.001
Control 117.84 ± 37.53 95.56 ± 28.90 0.019
UC 96.92 ± 35.63 66.29 ± 30.25 0.007
CD 87.40 ± 27.24 66.93 ± 25.24 0.014
Data are presented as Mean ± SD
ANOVA test was used to assess Metrnl levels, among three groups based on
BMI cutoff (Overweight, BMI ≥ 25 and normal weight, BMI < 25)
Abbreviations: UC ulcerative colitis, CD Crohn’s disease
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Correlation analysis
Correlation analyses were performed in 2 subgroups, as
controls and patients and the results are presented in
Table 4. In the control group, Metrnl was found to be
inversely correlated with BMI (Fig. 2). Metrnl also had
an inverse correlation with BMI, IL-6, and TNF-α, and a
positive correlation with FBG in the patient groups (Fig.
2).
Discussion
Adipokines, have regulatory roles on expression and se-
cretion of various cytokines, by this fact they have sig-
nificant effects on the immune system. Therefore, they
can play a crucial role in inflammatory diseases like IBD,
which also have a metabolic background [17]. Several
studies have shown that, adipokines such as leptin, resis-
tin, visfatin, retinol-binding protein-4, adiponectin,
glucose, and insulin are deregulated in the IBD patients
[13]. Metrnl is a novel adipokine, which has a major role
in improvement of inflammation and insulin resistance
improvement [18]. Accordingly, this adipokine has been
investigated in several metabolic and inflammatory dis-
eases. Lee et al. showed that, patients with diabetes mel-
litus type 2 (T2DM) had lower level of Metrnl in their
serum [19]. Similarly, Dadmanesh et al. found that
Metrnl concentration in the serum of patients with cor-
onary artery disease and T2DM were lower [20]. While,
Chung et al. reported that levels of Metrnl were signifi-
cantly higher in T2D patients [21]. Results of Wanng
et al, also represented increase in serum level of Metrnl
in T2M patients in comparison to control. They pro-
posed increase in serum Metrnl could strengthen the
risk of T2DM independent of insulin resistance [22].
This contradiction might be a results from the difference
in study population, diabetes duration and medication.
Most of the previous studies have focused on the tissues
level of Metrnl in inflammatory disorders, thus there is
no data on the serum levels of Metrnl in these complica-
tions. Bridgewood et al. investigated the level of Metrnl
in synovial tissue in the patients with Rheumatoid Arth-
ritis, Psoriatic Arthritis, and Osteoarthritis. As a result,
they found the elevated level of Metrnl in Psoriatic Arth-
ritis [23]. To the authors knowledge, so far, current
study is the novel one that reporting the serum levels of
Metrnl in the IBD patients. In addition, the results show
the lower serum levels of Metrnl in the IBD patients
compared to the controls. However, Metrnl was not dif-
ferent between patients groups. Li et al. demonstrated
that, Metrnl is highly expressed in the gastrointestinal
tract of normal donors as well as mice. On the other
hand, they produced intestinal epithelial cell-specific
knockout mice, in spite of reduction in Metrnl expres-
sion in the gastrointestinal tract, it’s level is not de-
creased in serum [16]. A recent study performed by Zuo
et al. reported that Metrnl expression is higher in mes-
enteric adipose tissue (MAT) of the CD patients com-
pared to the controls. They also showed that, systemic
treatment of Metrnl can improve the adipocyte function,
and reduce the macrophage infiltration and inflamma-
tion by acting on the peroxisome proliferator-activated
receptors (PPARγ) pathway in mice. Therefore, they
Table 3 Odd ratio of diseases status according to 10 unit change in the serum levels of Metrnl
Model Group Odd Ratio (95% CI) β (standard error) P value Correct prediction (%)
Crude UC 0.833 (0.735–0.944) − 0.183(0.064) 0.004 57.1
CD 0.760 (0.661–0.874) − 0.275(0.071) < 0.001 69.8
Model 1 UC 0.794 (0.692–0.912) − 0.230(0.070) 0.001 57.1
CD 0.738 (0.636–0.858) − 0.303(0.076) < 0.001 58.1
Abbreviations: UC ulcerative colitis, CD Crohn’s disease, CI Confidence interval
Model 1. Adjusted for age, sex and BMI
Table 4 Correlation analysis of serum Metrnl levels with
anthropometric and biochemical variables
Metrnl
Control IBD
BMI (kg/m2) −0.298* − 0.391**
Age (year) 0.174 −0.146
SBP (mmHg) −0.026 0.032
DBP (mmHg) −0.110 −0.061
FBG (mg/dl) 0.023 0.222*
Insulin (uU/ml) −0.184 0.085
HOMA-IR −0.175 0.127
TG (mg/dl) 0.202 −0.004
TC (mg/dl) 0.082 −0.016
LDL-C (mg/dl) 0.026 −0.061
HDL-C (mg/dl) 0.085 −0.029
Adiponectin (ug/ml) −0.012 −0.076
TNF-α (pg/mL) 0.137 −0.380**
IL-6 (pg/ml) −0.027 −0.324**
Abbreviations: UC ulcerative colitis, CD Crohn’s disease, SBP systolic blood
pressure, DBP diastolic blood pressure, FBG fasting blood glucose, HOMA-IR
homeostasis model assessment of insulin resistance, LDL-C low-density
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suggested that, upregulation of Metrnl in the MAT of
the patients may be a compensatory response [14]. Re-
garding the inconsistent results, it seems likely that,
Metrnl expression can have an organ dependent pattern;
however, further longitudinal research is needed to sup-
port this hypothesis.
Furthermore, present study indicated an inverse rela-
tionship of Metrnl with the inflammatory cytokines in
the IBD patients. It was also observed that, Metrnl may
have regulatory action in inflammation pathways. Zuo
et al. administered the Metrnl in IL-10−/− mice and
then observed a significant decrease in the score of in-
flammation and pro-inflammatory factors such as TNF-
α, interferon (IFN)-γ, and IL-6 [12]. Additionally, Zhi-
yong LI et al. reported that, Metrnl plays a regulatory
role in the expression of antimicrobial peptides such as
islet-derived 3 gamma (Reg3g), lactotransferrin, and
amyloid A-3 (SAA3) [23]. Since TNF-α and IL-6 are
considered as the markers of inflammation, the results
suggest a relationship between Metrnl and IBD patho-
genesis. In addition, adiponectin decreased in the pa-
tient’s groups, however, there were no relation between
Metrnl and adiponectin that suggested a different regu-
lation of these two adipokines.
When the population were stratified based on obesity,
the serum level of Metrnl was significantly lower in
Fig. 2 The correlation of Metrnl with a) BMI in controls, b) BMI in patients, c) FBG in patients, d) TNF-α in patients and e) IL-6 in patients. BMI,
body mass index; TNF-α, Tumor Necrosis Factor Alpha; IL-6, Interleukin 6
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obese subjects than in non-obese ones. Consistently,
AlKhairi et al. reported that, Metrnl is significantly
higher in the T2DM obese patients, in a way that this
elevation can be explained as a compensatory response
[24]. However, Zhi-Yong Li et al. showed no correlation
between serum Metrnl levels and BMI [25]. As the adi-
pose tissue is the main source of Metrnl secretion, it is
expected that, BMI can affect the levels of this adipo-
kine, and adipose tissue inflammation and dysfunction
may be considered as the causes for the decrease in
Metrnl levels.
Study strength and limitations
The present study for the first time measured Metrnl
serum levels in patients UC and CD disease and its rela-
tion with inflammatory cytokines. The studied popula-
tion were matched in terms of age, sex and BMI with
control group that eliminated the impact of these con-
founding factor on the results. On the other hand, the
present study has no data on body fat distribution that
could be more clinically significant than BMI. Further-
more, the cross-sectional design of the study limited us
in concluding a cause and effect relationship, so further
studies are waranted to dissect the possible mechanism
for the reported relationship.
Conclusion
In conclusion, the current study for the first time
showed that a decreased level of Metrnl in the serum of
IBD patients. Moreover, it was found that, serum level of
Metrnl has a negative correlation with levels of TNF-α,
IL-6 and BMI in the serum of patients with IBD.
Altogether, the present study found that Metrnl, inflam-
mation, and obesity are related. This finding may suggest
a possible association of Metrnl with the pathogenesis of
IBD which can be considered for ameliorating the in-
flammatory milieu in these patients.
Abbreviations
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